A study by Zhang et al. [46] showed that xenograft tumors that derive from cancer cells with low expression levels of BDH1 and OXCT1 are more responsive to KD therapy, probably because they possess a lower ability to metabolize KB. This evidence concerns the gene BDH1 and cancer.